VisEn Seeks to Image from Bench to Bedside | GenomeWeb

When it comes to the clinic, seeing is more than believing -- it's also a first step to intervening in the progression of disease. So while genomics and proteomics technologies may yield first evidence that something is off in a system, the real clinical payoff comes when one can map the molecular consequences of a condition or drug response in a living biological setting. To that end, VisEn Medical has developed bioimaging tools that the company says are able to return quick, measurable, and physiologically deep read-outs in living animals.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.